The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -16.52 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M 2.03 — flag raised, worth a closer lookWatch
- Earnings quality 71/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as INTERPACE BIOSCIENCES, INC. reports it. History and quarterly detail are in the app.
- Reportable$38.7M
Leadership changes
From INTERPACE BIOSCIENCES, INC.'s own filings, the day they're filed.
- Robert Gorman · director · departureeff. 2023-12-07
- Edward Chan · director · departureeff. 2023-11-15
- Christopher McCarthy · Chief Financial Officer · appointmenteff. 2023-07-24
Latest filings
- 8-K · Company announcement2026-08-27
- 8-K · Company announcement2026-08-21
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-10
- DEF 14A · Annual proxy (pay & governance)2026-07-07
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about INTERPACE BIOSCIENCES, INC., every answer cited to the official filings🔒
- The Intelligence Brief — added when INTERPACE BIOSCIENCES, INC.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.